Drugs / Prothione
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04742725 | May → Sep 2021 | COVID-19 | Prothione, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prothione | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04742725 ↗ |
| Route | Oral | “Prothione™ capsules administered orally twice a day for 30 days” NCT04742725 ↗ |